Back to Search
ANN LACASCE, M.D.
M.D.
Medical Oncology Physician
NPI: 1336156983IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
156957(MA)
Education
TUFTS UNIVERSITY SCHOOL OF MEDICINE
Class of 1996
Research & Publications (19)
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.
PMID 18768434·J Clin Oncol·2008
4-observational
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
PMID 18381102·Semin Hematol·2008
6-review
Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
PMID 15160953·Leuk Lymphoma·2004
3-trial
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
PMID 19541793·Ann Oncol·2009
8-other
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
PMID 19001324·J Clin Oncol·2008
4-observational
Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database.
PMID 18855918·Cancer·2008
8-other
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant.
PMID 18798108·Leuk Lymphoma·2008
8-other
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.
PMID 18729853·Br J Haematol·2008
8-other
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
PMID 18342784·Biol Blood Marrow Transplant·2008
8-other
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
PMID 17389337·J Clin Oncol·2007
3-trial
Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
PMID 17197926·Am J Surg Pathol·2007
8-other
Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
PMID 16805709·Expert Opin Biol Ther·2006
6-review
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
PMID 16507273·J Natl Compr Canc Netw·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET #DIB05
BOSTON, MA 02115 - Phone
- (617) 632-5959
Quick Facts
- NPI
- 1336156983
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 30
- Publications
- 19
Are you this provider?
Claim Your Profile